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SBackground: Esophagectomy has been the traditional therapy for high-grade dysplasia and intramucosal ade-
nocarcinoma. New endoscopic approaches allow treatment of these lesions with esophageal preservation. The
aim of this study was to compare the outcome of endoscopic therapy with esophagectomy for high-grade dys-
plasia and intramucosal cancer.
Methods: A retrospective review was performed of all patients treated for high-grade dysplasia or intramucosal
adenocarcinoma from 2001 to April 2010.
Results: Endoscopic therapy was performed in 40 patients (high-grade dysplasia ¼ 22, intramucosal
cancer ¼ 18) and esophagectomy in 61 patients (high-grade dysplasia ¼ 13, intramucosal cancer ¼ 48). Endo-
therapy consisted of 102 endoscopic resections and 79mucosal ablations (median 3 interventions per patient). In
the endotherapy group, intramucosal cancer was completely resected in all patients. At last assessment, 10 pa-
tients have been converted to intestinal metaplasia without dysplasia and 21 to no residual intestinal metaplasia.
Five patients have follow-up biopsy procedures pending after recent ablation, and esophagectomy was
performed in 3 patients for failed endotherapy. A laparoscopic Nissen fundoplication has been performed in
8 patients after eradication of intestinal metaplasia. Esophagectomy resected the mucosal disease with negative
margins in all patients. Compared with esophagectomy, endotherapy was associated with significantly lower
morbidity (39% vs 0; P< .0001) and similar survival (94% at 3 years in both groups; median follow-up
34 months after esophagectomy vs 17 months after endotherapy; P ¼ .0026).
Conclusions: Endoscopic therapy for high-grade dysplasia or intramucosal cancer has lower morbidity than an
esophagectomy and similar survival during short-term follow-up, but required multiple procedures in most
patients. Both therapies are appropriate options, but preservation of the esophagus allows the option of a fundo-
plication for reflux control, perhaps further improving long-term quality of life. (J Thorac Cardiovasc Surg
2011;141:39-47)The incidence of esophageal adenocarcinoma and its precur-
sor lesion, Barrett’s esophagus, continues to increase in the
United States and other Western countries.1-4 Surveillance
programs have identified an increasing number of patients
with high-grade dysplasia or intramucosal adenocarcinoma,
for whom traditional therapy has been an esophagectomy.
Although usually curative, esophagectomy is associated
with considerable early and long-term morbidity.
Recently, the introduction of endoscopic techniques for
resection of superficial lesions and ablation of the Barrett’s
mucosa has allowed the option of esophageal preservation
in patientswith high-grade dysplasia or intramucosal cancer.e Department of Surgery, Keck School of Medicine, University of Southern
ornia, Los Angeles, Calif.
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The Journal of Thoracic and CThe largest series of patients treated endoscopically for these
lesions were reported from gastroenterology units in Wies-
baden and Amsterdam.5-7 Morbidity was low and survival
excellent in these series; however, they are uncontrolled in
that patients with the more complex conditions may have
been referred for surgical therapy. We adopted endoscopic
therapy in 2001, and the aim of this study was to compare
the morbidity, mortality, survival, and cancer recurrence
rates in concurrent patients with high-grade dysplasia or in-
tramucosal cancer treated either with endoscopic therapy or
esophagectomy in a surgical unit.
PATIENTS AND METHODS
We performed a retrospective review of the records of all patients with
high-grade dysplasia or intramucosal adenocarcinoma treated endoscopi-
cally or by an esophagectomy at our institution from 2001 (when we started
doing endoscopic therapy) through April 2010. Patients with tumors inva-
sive into the submucosa were excluded, but lymphovascular invasion or
poor differentiation in an intramucosal lesion did not deter endoscopic
therapy. This study was approved by the Institutional Review Board of
the University of Southern California.
Evaluation and Definitions
All patients were evaluated with upper endoscopy. Barrett’s esophagus
was defined as an endoscopically visible segment of columnar mucosa withardiovascular Surgery c Volume 141, Number 1 39
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segment if the length of columnar mucosa was 3 cm or longer. Biopsy spec-
imens were taken in all patients from the antrum and gastric body, gastro-
esophageal junction, and every 1 to 2 cm from the gastroesophageal
junction to the squamocolumnar junction. Additional biopsy samples
were taken from any nodules or ulcers within the columnar mucosa.
Patients with confirmed cancer were selectively evaluated with endoscopic
ultrasound for locoregional staging and computed tomography (CT) and
positron emission tomography (PET) scans for systemic staging. Patients
considered for endoscopic therapy had a videoesophagogram to evaluate
for the presence and size of a hiatal hernia and assess esophageal body
bolus transport function when warranted by symptoms.
Technique of Endoscopic Therapy
All endoscopic resections were performed as an outpatient procedure
in the operating room under general anesthesia by thoracic/foregut sur-
geons. Visible lesions were excised with endoscopic resection, and the
depth of invasion was pathologically determined in the fixed specimen.
Endoscopic resection was performed by the Inoue cap technique with ei-
ther the straight 13.9-mm or the soft, oblique 18-mm Olympus cap
(Olympus Corporation, Shinjuku-ku, Japan) after dilute epinephrine in sa-
line was injected into the submucosa to lift the lesion.8 Multiple resec-
tions were performed at a single setting, but never circumferential or
exceeding 3 cm in height at one site.
Ablation was usually performed with either the Halo 360 or the Halo 90
(Halo systems;BARRXMedical Inc, Sunnyvale,Calif) radiofrequency cath-
eters at the recommended energy setting (12 J/cm2). Occasionally, argon
plasma coagulation was used to touch up small areas, typically at the time
of endoscopic resection of a lesion. In some patients immediately after endo-
scopic resection of a nodule, the surrounding Barrett’s mucosa was ablated
with theHalo 90device.Ablationwas not performedover areas just resected.
Follow-up After Endoscopic Therapy
An endoscopy with biopsies was done 8 weeks after endoscopic resec-
tion or ablation. Biopsy specimens were taken using the same protocol as
before therapy, but in addition, samples of the neosquamous mucosa were
taken, looking for buried glands, in areas where columnar mucosa had
been. If residual Barrett’s esophagus was present, most patients were im-
mediately scheduled for further endoscopic resection or ablation. If no in-
testinal metaplasia was present, repeat endoscopywas done every 3 months
for 1 year, then every 6 months for 1 year, and then annually. Elimination of
intestinal metaplasia was accepted only after 2 consecutive endoscopies
with biopsies showed no intestinal metaplasia and no buried glands. Pa-
tients with cancer were followed up clinically, and posttherapy endoscopic
ultrasound, CT, and PET scans were not routinely obtained.
Reflux Management
During endoscopic therapy, patients were maintained on twice a day
proton pump inhibitor therapy. Once all the intestinal metaplasia was erad-
icated, our preference was to perform a Nissen fundoplication for long-
term reflux control and protection of the neosquamous mucosa. Before
antireflux surgery, an esophageal manometry was performed as previously
described.940 The Journal of Thoracic and Cardiovascular SurgeEsophagectomy
Esophagectomy was performed as a transthoracic en bloc, transhiatal,
minimally invasive, or vagus-sparing resection as previously described.10,11
Reconstruction in all cases was with a tubularized gastric pull-up. Patients
were followed up clinically by the operating surgeon after the esophagec-
tomy for any evidence of recurrence, with selective use of CTor PET scans.
Classification of Complications
Complications were classified as either minor or major. Minor compli-
cations were defined as those not requiring interventional procedures or re-
operations. Anastomotic leaks after esophagectomy were classified as
major complications and divided into minor leaks if treated with antibiotics
alonewithout interventional procedures, stenting, or reoperation. A leak re-
quiring any intervention was classified as a major leak. Procedure-related
mortality consisted of any death within 30 days or before hospital
discharge.
Statistical Analysis
Data are expressed as medians and interquartile range (IQR). Compar-
isons of proportionswere performed using the Fisher exact test. Continuous
variables were compared using the Mann–Whitney test. Survival was cal-
culated by the Kaplan–Meier method and compared using the log–rank
method.RESULTS
Endoscopic therapy was performed in 40 patients and
esophagectomy in 61 patients (Table 1). The median age,
gender, and length of Barrett’s esophagus was similar in
both groups. The prevalence of high-grade dysplasia was
significantly higher in the endotherapy group, whereas intra-
mucosal cancer was more prevalent in the esophagectomy
group. There was no significant difference in the prevalence
or types of comorbid conditions. Median follow-up was
significantly longer after esophagectomy (endoscopic
therapy: 17 months [IQR, 9–29 months]; esophagectomy:
34 months [IQR, 19–51 months]; P ¼ .0026).Endoscopic Therapy
Procedure. The 40 patients with endoscopic therapy had
a median of 3 interventions per patient, consisting of 102 en-
doscopic resections and 79 mucosal ablations. The maxi-
mum number of treatment sessions was 8 in 1 patient. The
endoscopic resections were performed in 53 sessions with
1 to 3 specimens retrieved for histopathologic analysis at
each session. Mucosal ablation was performed with the
360 radiofrequency balloon 16 times, with the 90 device
51 times, and with the argon plasma coagulator 12 times.
Complications. There were no perforations during endo-
scopic resection or ablation, and no patient had bleeding re-
quiring endoscopy or transfusion. All patients were
discharged home on the day of the procedure. No patient
had a stricture that required dilatation. Mild chest discom-
fort was common for several days after ablation, but there
were no other procedure-related complications or symp-
toms. On follow-up endoscopic biopsies, buried Barrett’s
tissue was found in only 1 patient who had had ablation
with argon plasma coagulation. No buried Barrett’s tissuery c January 2011
TABLE 1. Patient characteristics
Endoscopic
therapy
group (n ¼ 40)
Esophagectomy
group (n ¼ 61)
P
value
Median age in years (IQR) 66 (58–76) 68 (58–75) .84
Gender male/female 33/7 49/12 1.0
Median length of Barrett’s
esophagus, cm (IQR)





High-grade dysplasia 22 (55%) 13 (21%) .0007
Intramucosal cancer 18 (45%) 48 (79%) .0007
Lymphovascular invasion 6% 2% .44
Poor differentiation 6% 8% 1.0
Visible lesion 22 (55%) 49 (80%) .0081
Comorbid conditions
Cardiac disease 11 (28%) 22 (36%) .40
Respiratory disease 17 (43%) 20 (33%) .40
Hypertension 23 (58%) 32 (52%) .69
Renal disease 3 (8%) 7 (11%) .74
Diabetes mellitus 7 (18%) 7 (11%) .40
Tobacco abuse 16 (40%) 27 (44%) .69
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quency ablation.
Outcome
Intramucosal cancer. Eighteen patients were treated en-
doscopically for an intramucosal cancer (Figure 1, A). In
16 patients a visible lesion was present, and all had endo-
scopic resection of the lesion. All resection margins were
negative. In 11 patients invasion was into the lamina propria
whereas in 5 there was invasion into but not through the
muscularis mucosa. After initial endoscopic resection, 1 pa-
tient on rebiopsy had no residual Barrett’s tissue whereas
the other 15 patients underwent additional endoscopic pro-
cedures for residual Barrett’s esophagus with or without
dysplasia. One of these 15 patients ultimately had an esoph-
agectomy for persistent high-grade dysplasia after 3 endo-
scopic procedures. The final pathologic report on the
resected specimen in this patient showed multifocal high-
grade dysplasia without adenocarcinoma.
There was no visible lesion in 2 patients with a biopsy
showing adenocarcinoma, and both patients were treated
with radiofrequency ablation. Subsequent endoscopy in 1 of
the patients showed a lesion that was endoscopically resected
and proved to be an intramucosal cancer. Biopsy specimens in
this patient after further endotherapy now show no intestinal
metaplasia. The other patient is still undergoing ablation for
residual intestinal metaplasia, but there is no dysplasia.
None of the 17 patients with intramucosal cancer treated
endoscopically without esophagectomy progressed toThe Journal of Thoracic and Csubmucosal cancer, but metachronous cancers developed
in 3 (18%) patients. All 3 patients had residual Barrett’s
esophagus or dysplasia on biopsy specimens immediately
before the identification of the cancer. At the time of the
last follow-up endoscopic examination, 9 (53%) of the 17
patients no longer had intestinal metaplasia and 14 (82%)
were free of dysplasia or cancer. A laparoscopic Nissen
fundoplication had been performed in 2 patients treated
endoscopically for intramucosal cancer to correct the path-
ophysiology of their reflux disease.
High-grade dysplasia. Twenty-two patients were treated
endoscopically for high-grade dysplasia (Figure 1, B). En-
doscopic resection was performed in 10 patients, 6 with
a visible lesion that proved not to be cancer after resection
and 4 with a short tongue of Barrett’s esophagus believed to
be amenable to complete endoscopic resection. The other
12 patients underwent radiofrequency ablation as the initial
therapy. Additional endoscopic procedures were necessary
in 13 patients. Of these 22 patients, 1 died of causes unre-
lated to esophageal disease, and 2 had an esophagectomy
for persistent high-grade dysplasia. Among the remaining
19 patients, progression to cancer occurred in 5 (26%) be-
fore complete ablation of intestinal metaplasia, and all were
successfully treated with endoscopic resection. In 4 patients
the cancer was intramucosal and in 1 it was submucosal. All
endoscopic resection margins were clear, no patient has had
recurrent cancer, and no patient went on to esophagectomy
(the patient with submucosal invasion declined esophagec-
tomy and at 12 months of follow-up remains free of
disease). At the time of last biopsy, 17 (89%) of the 19 pa-
tients treated endoscopically for high-grade dysplasia had
either no intestinal metaplasia (n ¼ 12) or intestinal meta-
plasia without dysplasia (n¼ 5). From this group, 6 patients
have had a Nissen fundoplication.
Length of Barrett’s esophagus and success with endo-
scopic therapy. The median length of Barrett’s esophagus
before endoscopic therapy was 3 cm (range, 1–11 cm). In
the 21 patients with complete eradication of intestinal meta-
plasia, the median number of treatment sessions necessary
was significantly fewer in patients with short- versus long-
segment Barrett’s esophagus (median 2 for short segment
vs 5 for long segment; P ¼ .047). The median time to com-
plete eradication of intestinal metaplasia was 20 months
(IQR, 14–28 months). The relationship between length of
Barrett’s esophagus and the number of treatment sessions is
shown in Figure 2.
Primary Esophagectomy
Procedure. Esophagectomy was done for high-grade dys-
plasia in 13 patients and intramucosal adenocarcinoma in
48 patients. The esophagectomywas done as a transthoracic
en bloc procedure in 11 patients, a transhiatal procedure in
20 patients, and a vagus-sparing procedure in 30 patients.
In 10 patients, the vagus-sparing esophagectomy wasardiovascular Surgery c Volume 141, Number 1 41
FIGURE 1. A, Flow chart for the 18 patients with intramucosal cancer. B, Flow chart for the 22 patients with high-grade dysplasia. ER, Endoscopic re-
section; RFA, radiofrequency ablation; IM, intestinal metaplasia; HGD, high-grade dysplasia; IMC, intramucosal cancer.
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quency of an en bloc resection decreased whereas the
vagus-sparing esophagectomy increased. A staging endo-
scopic resection had been performed in 20 (33%) patients
before vagus-sparing esophagectomy to confirm the depth
of invasion of a visible lesion. In the 48 patients with intra-
mucosal cancer, a total of 921 lymph nodes were removed,42 The Journal of Thoracic and Cardiovascular Surgeand only 1 node in 1 patient was positive for metastatic
cancer by routine histologic examination (2.1%).
Complications. Postoperative complications occurred in
39% of patients after esophagectomy (Table 2). There
was no mortality, including the 3 patients that had esopha-
gectomy for failed endoscopic therapy. Long-term compli-
cations occurred in 61% of patients and includedry c January 2011
FIGURE 2. Length of Barrett’s segment before endoscopic therapy,
number of treatment sessions, and pathology at the time of most recent
endoscopy and biopsy. IM, intestinal metaplasia.
FIGURE 3. Kaplan–Meier curve of overall survival for endoscopic ther-
apy (ET) and esophagectomy (ESO).
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dial dumping or diarrhea.
Outcome. After esophagectomy, all resectionmarginswere
free of intestinal metaplasia. In 1 (8%) patient who had
esophagectomy for high-grade dysplasia, a focus of intramu-
cosal cancer was found in the resected specimen, and among
the 48 patients who had an esophagectomy for confirmed ad-
enocarcinoma, multifocal cancer was found in the resected
specimen in 1 (2%) patient. One patient with intramucosal
cancer but no lymph node metastases died of systemic dis-
ease at 50 months after esophagectomy. No other cancer re-
currences have been detected, including the only patient who
had an involved lymph node at the time of resection.Comparison of Endotherapy With Esophagectomy
Over the years of the study there has been a shift at our
center from esophagectomy to endoscopic therapy forTABLE 2. Complications after esophagectomy for high-grade














Stricture requiring dilatation 17 (28%)
Reflux symptoms 36 (59%)
Nocturnal aspiration events 17 (28%)
Reoperation for incisional hernia 7 (11%)
Total 37 (61%)
The Journal of Thoracic and Chigh-grade dysplasia and intramucosal cancer, and cur-
rently approximately 80% of patients are treated endoscop-
ically. Early morbidity was significantly higher after
esophagectomy (39% vs 0; P < .0001); however, there
was no procedure-related mortality with either therapy. A
new or metachronous cancer developed in 8 (20%) patients
undergoing endoscopic therapy but in no patient after
esophagectomy. There was no difference in overall survival
between endotherapy and esophagectomy (94% at 3 years
in both groups; Figure 3). Cancer-related survival was
100% in both groups at 3 years and 100% in the endother-
apy group compared with 88% in the esophagectomy group
at 5 years (P ¼ .54).
Esophagectomy removed all the mucosal disease, and
there has been no recurrence of Barrett’s tissue in the resid-
ual cervical esophagus in any patient after esophagectomy.
In the endotherapy group all intestinal metaplasia has been
eradicated in 58% of patients, but the likelihood of com-
plete eradication increased with the duration of therapy
and follow-up. There were 26 patients who had endotherapy
and follow-up for a minimum of 1 year. In this group, all
intestinal metaplasia has been eradicated in 18 (69%) pa-
tients. Among 10 patients with at least 3 years of follow-
up, 80% have no intestinal metaplasia, and in the 4 patients
with at least 5 years of follow-up, 100% have no intestinal
metaplasia. Importantly, there has been no recurrence of
dysplasia or cancer in patients from whom all intestinal
metaplasia was eradicated, and none of these patients had
intestinal metaplasia redevelop during a median follow-up
of 8 months. A Nissen fundoplication has been performed
in 8 (20%) patients thus far after eradication of the mucosal
disease with endoscopic therapy.DISCUSSION
Esophageal adenocarcinoma remains a dreaded disease,
known for poor survival and difficult and life-alteringardiovascular Surgery c Volume 141, Number 1 43
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grade dysplasia or adenocarcinoma while still intramucosal
and the introduction of effective endoscopic therapies for
these lesions represent a major advance for the care and
outcome in these patients. Initial attempts at endoscopic
therapy in the 1980s were largely with photodynamic ther-
apy (PDT).12-15 Problems with PDT included the lack of
a specimen to confirm the depth of invasion if there was
a visible lesion, the high rate of stricture and buried
Barrett’s tissue, and the phototoxicity that accompanied
the procedure. The development of endoscopic resection
techniques that allow visible lesions to be excised and the
depth of invasion determined, as well as the introduction
of radiofrequency ablation that avoids many of the
problems with PDT, has launched endoscopic therapy into
the forefront for the management of patients with high-
grade dysplasia or superficial esophageal adenocarcinoma.
Before the extension of endoscopic therapy to the treat-
ment of superficial esophageal adenocarcinoma, it was nec-
essary for the biology of this tumor to be clearly defined. In
particular, an understanding of the important relationship
between the depth of tumor invasion and the risk of lym-
phatic metastases was critical. This information has been
provided by a number of surgical series in which it was
shown that tumors with invasion confined to the mucosa
rarely (<2%) have nodal metastases.11,16-18 Further, in
a comparison of resection techniques, we11 showed that
the type of esophagectomy and extent of lymphadenectomy
did not affect survival for an intramucosal adenocarcinoma.
Consequently, endoscopic resection is appropriate from an
oncologic standpoint for tumors limited to the mucosa. In
contrast, submucosal invasion is associated with an approx-
imately 20% risk of nodal metastases, and therapies that do
not address potentially involved lymph nodes are not appro-
priate.19
Esophagectomy has been the traditional therapy for high-
grade dysplasia and intramucosal cancer, and it is curative
in nearly all patients. Further, operative mortality rates for
these conditions, 0% to 1% in major centers, are much
lower than in patients with locoregionally advanced dis-
ease.20 However, morbidity remains significant. Since lym-
phadenectomy is not necessary for patients with high-grade
dysplasia or intramucosal cancer, we have scaled down the
resection and now preferentially use a vagus-sparing proce-
dure. This operation has reduced morbidity compared with
a standard esophagectomy with vagal disruption and can be
done laparoscopically.11 An advantage of esophagectomy,
as shown in this series, is that the therapy is immediate
and lasting. All resection margins were free of Barrett’s tis-
sue and no patient had intestinal metaplasia redevelop dur-
ing follow-up nor required further intervention for their
original condition. This is in stark contrast to the frequent
follow-up endoscopies and repetitive interventions usually
necessary in the endotherapy group. Further, although 1 pa-44 The Journal of Thoracic and Cardiovascular Surgetient with a preoperative diagnosis of high-grade dysplasia
was found to have a focus of invasive adenocarcinoma after
esophagectomy, the other 12 patients had only high-grade
dysplasia and are therefore at no risk of death from meta-
static esophageal adenocarcinoma. In contrast, in the endo-
therapy group, 26% of patients who started therapy with
only high-grade dysplasia progressed to invasive cancer
and have incurred the potential risk, although very small,
for death from metastatic disease.
Despite the immediacy and finality of treatment with
esophagectomy, the potential for early and long-term
complications as well as the magnitude of the procedure
discourage patients from having the operation. This is re-
flected by the shift in management of patients with high-
grade dysplasia and intramucosal adenocarcinoma seen at
our center and other major esophageal centers worldwide,
where most patients now undergo endoscopic therapy
with the goal of preserving the esophagus. In our series, en-
dotherapy was associated with a significant reduction in
morbidity with equivalent short-term survival compared
with an esophagectomy. In fact, the only death from cancer
was in a patient who had an esophagectomy. We recognize
that our study is limited by small numbers and shorter
follow-up in the endotherapy group. Nonetheless, we have
4 patients who were endoscopically treated for an intramu-
cosal cancer with follow-up to 3 years and 3 with follow-up
to 5 years, and none has demonstrated metastatic disease.
Further, large experiences from Amsterdam andWiesbaden
have shown excellent survival with endoscopic resection
and ablation for high-grade dysplasia and intramucosal can-
cer.5-7 The absence of cancer deaths in these series is
surprising and suggests that perhaps a limited endoscopic
resection has less impact on the immune system than an
esophagectomy and further reduces the already small risk
of metastatic disease in these patients. Alternatively, the
follow-up in these series may be too short for micrometa-
static disease in lymph nodes or elsewhere to become clin-
ically evident. At this time, though, it is reasonable to
conclude that the risk of metastatic disease is not higher
with endoscopic therapy compared with an esophagectomy
for intramucosal cancer.
Despite the willingness of most patients to have endo-
scopic therapy, in our opinion selection is important inas-
much as not every patient is an appropriate candidate for
endoscopic therapy. There are 3 factors that we consider
in our evaluation: tumor factors, esophageal factors, and pa-
tient factors (Table 3). We recommended esophagectomy to
several patients in this series with multifocal high-grade
dysplasia or intramucosal cancer thought to be too extensive
for endotherapy, or with end-stage reflux disease in which
esophageal preservation did not make sense. We also per-
formed an esophagectomy in 3 patients after failed attempts
at endotherapy. Avagus-sparing esophagectomy remains an
excellent option for these patients and was not precluded byry c January 2011
TABLE 3. Factors considered in the selection of patients for
esophageal preservation with endotherapy
Tumor factors
1. High-grade dysplasia or intramucosal cancer (no submucosal tumors
owing to risk of lymph node metastases)
2. Visible lesions resected with negative deep margins (positive lateral
margins acceptable with additional endotherapy)
3. All intestinal metaplasia can be successfully eradicated
Esophageal factors
1. Esophagus is worth saving (no end-stage reflux disease)
2. Reflux disease controlled with proton pump inhibitor medications (no
severe heartburn, regurgitation, aspiration, or dysphagia symptoms)
3. Acceptable bolus transport on videoesophagogram or peristalsis on
motility study (candidate for Nissen fundoplication)
Patient factors
1. Patient able to understand pros and cons of each approach
2. Patient able to live with the uncertainty of complete mucosal disease
eradication, potential for buried glands, and potential for cancer
development or recurrence, perhaps at more advanced stage
3. Patient willing and able to return to our center for repeat follow-up
endoscopies with or without additional endoscopic resections or
ablations on a frequent basis, at least early in the therapy
4. Patient understands that endotherapy may fail and they might require
esophagectomy anyway
5. Patient understands that antireflux surgery is recommended once all
intestinal metaplasia has been successfully eradicated
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esophagectomy for persistent disease after 3 attempts at en-
dotherapy, but in some cases when the initial radiofre-
quency ablation had minimal impact on the diseased
mucosa we recommended an esophagectomy earlier. All
of the patients who went on to esophagectomy had long-
segment Barrett’s esophagus (6, 7, and 10 cm), and long
segments of Barrett’s tissue are more difficult to eradicate
than short segments. However, there were 7 patients with
similar or longer segments of Barrett’s tissue that were suc-
cessfully ablated to no intestinal metaplasia or to nondys-
plastic Barrett’s tissue, and consequently patients with
long-segment Barrett’s esophagus should not be excluded
from an attempt at endotherapy. Another consideration is
that radiofrequency ablation was the primary mode of abla-
tion attempted in the 3 patients who went on to esophagec-
tomy for failed endotherapy. It is possible that greater use of
endoscopic resection might have allowed salvage of the
esophagus in these patients. We avoided overlapping resec-
tions using the Inoue cap technique, and because of the con-
cern for a ‘‘cookie-cutter’’ issue with nonoverlapping
resections, where residual Barrett’s tissue would be left be-
tween resection sites, we reserved endoscopic resection
largely for removal of lesions. Recently, we have switched
to the band ligator device for endoscopic resection, and this
seems to permit safer and easier overlapping resections. Pa-
tients with areas of Barrett’s esophagus refractory to radio-
frequency ablation can have stepwise radical endoscopicThe Journal of Thoracic and Cresection, as others have reported.21 Using this technique,
we likely will be able to reduce the number of patients
with failed endotherapy in the future. In addition, new abla-
tion modalities such as cryoablation may treat areas refrac-
tory to radiofrequency energy.22
An advantage of endotherapy, in addition to the safety and
lowmorbidity of the procedure, is the fact that ultimately re-
flux can be eradicated with an antireflux procedure, whereas
after an esophagectomy patients have life-long potential for
reflux, regurgitation, and aspiration. During endotherapy,
we prefer intensive medical treatment for reflux and delay
a fundoplication until all the intestinal metaplasia has
been eradicated for approximately 1 year to avoid having
to do an esophagectomy for recurrent or persistent disease
after performing a fundoplication. This approach is perhaps
too conservative, and early and effective control of reflux
during endotherapywith a fundoplicationmay be beneficial,
particularly in patients with refractory Barrett’s esophagus
or dysplasia. Future studies will provide insight into the
optimal timing for antireflux surgery in these patients.
Although endotherapy is preferred by most patients, it is
burdensome for both the patient and physician. The median
number of procedures in our series was 3, and in 1 patient 8
procedures were performed. The goal of endotherapy must
be complete eradication of all intestinal metaplasia inas-
much as any residual intestinal metaplasia is at risk for
progression. A new or metachronous intramucosal cancer
developed in 8 of our patients while undergoing endother-
apy before successful eradication of all intestinal meta-
plasia. In retrospect, in some of these patients the
endotherapy schedule should have been more aggressive,
because delays in scheduling another ablation accounted
for some of the progression. This risk of metachronous tu-
mor development was also seen in the series from Wiesba-
den, where initially tumors were excised endoscopically but
the residual Barrett’s esophagus was not being ablated.6
Subsequently, ablation for the residual Barrett’s esophagus
has been added to their protocol, and cancer recurrence has
been reduced.23 Given this risk, we recommend repeated re-
sections and ablations on a 2-month schedule until all intes-
tinal metaplasia has been eradicated. In patients in whom all
the intestinal metaplasia or dysplasia cannot be eradicated,
consideration should be given to an esophagectomy.
Despite the workload for endotherapy, it is associated
with minimal complications and is well tolerated by pa-
tients. We have had no episodes of significant bleeding,
no perforations, and no strictures. However, we limit the ex-
tent of resection at any one time and prefer to do repeat pro-
cedures rather than be overly aggressive at one setting. This
may account for the safety and minimal complications we
have observed. As the number of patients in various stages
of treatment and follow-up increase, it becomes a significant
burden on the office staff to keep them all organized, and the
patients need to stay engaged in the process to make sureardiovascular Surgery c Volume 141, Number 1 45
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further magnified by an increasing number of patients un-
dergoing endoscopic therapy and continued economic chal-
lenges in medicine, particularly related to the poor
reimbursement for these procedures.
In conclusion, both endoscopic therapy and esophagec-
tomy are appropriate treatment options for patients with
high-grade dysplasia or intramucosal adenocarcinoma.
Although morbidity is increased with esophagectomy
compared with endotherapy, esophagectomy is generally
a 1-shot treatment. In contrast, the majority of patients un-
dergoing endoscopic therapy require multiple interventions
and remain at risk for cancer development until all the intes-
tinal metaplasia has been eradicated. Failure to aggressively
eradicate all Barrett’s tissue and carefully monitor these pa-
tients sets the stage for recurrent cancer, and could poten-
tially change a largely curable condition into a fatal
disease. Although endoscopic therapy has revolutionized
the therapy for high-grade dysplasia and intramucosal can-
cer, it is critical to not forget the lethality of this cancer and
get nonchalant in patients fortunate enough to be found with
a lesion that is nearly always curable.
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Dr Ross M. Bremner (Phoenix, Ariz). One year ago at this
meeting we discussed the optimal treatment of patients with
very early esophageal cancer at a breakfast meeting, referring of
course to patients with high-grade dysplasia and intramucosal car-
cinoma. Since these patients rarely, if ever, have the potential for
lymph node or metastatic spread, local therapies are probably ap-
propriate. Our experiences with the techniques of endoscopic re-
section and radiofrequency and cryoablation are relatively
limited. The work that we have heard this morning probably rep-
resents the largest US experience, and, although this is a retrospec-
tive review, I congratulate the authors on their impressive data and
a very thoughtful and well-written manuscript. I do have a couple
of questions.
One of the problems with embarking on an endoscopic protocol
is relying on the biopsy protocols that we do inasmuch as they in-
troduce a possible sampling error from the biopsy specimens. How
do we know that we have sampled adequately and can we be reas-
sured that we are not missing a more advanced cancer? In that re-
gard, is there any value for narrow-band imaging, vital dyes, and
perhaps high-frequency ultrasound to help our biopsy techniques?
Dr DeMeester. Yes, that is an important issue. I think narrow-
band imaging is probably useful. It is much easier than vital
sprays and dyes, which are fairly complicated, time consuming,
and a bit of a nuisance. The reality is, if you follow a Seattle pro-
tocol—4-quadrant biopsies every 1 to 2 cm throughout the length
of the columnar mucosa—you do not miss many lesions. You get at
least a feel for what is going on. I think it is less of an issue of miss-
ing high-grade dysplasia than actually the pathologist being
wrong, and it is important to have a good pathologist interpret
the pathology.ry c January 2011
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SIn terms of when there is high-grade dysplasia, is there also an
invasive cancer that you do not know about? Multiple surgical se-
ries of esophagectomies have shown that almost 50% of the time
there will be an associated adenocarcinoma that has not been iden-
tified. However, a number of years ago John Nigro presented our
paper on that. If you have a high-grade dysplasia and a focus of
invasive cancer, in almost all cases the lesion is limited to the mu-
cosa. It would be rare to have an invisible lesion penetrating into
the submucosa, so you do not need to worry about that in general.
You can reliably ablate high-grade dysplasia and nonvisible
cancers with the techniques available today.
Dr Bremner. I agree that embarking on an endoscopic protocol
is pretty labor intensive inasmuch as it requires multiple therapies
and continued follow-up. Quite frankly, it is a little nerve-wracking
when you start doing this on otherwise healthy younger patients.
However, once cured, swallowing with one’s own esophagus is in-
tuitively better than swallowing with a gastric tube. Have you done
any long-term quality of life indices to help us understand this bet-
ter, or are you planning to do this once you have longer follow-up?
Dr DeMeester. That is an important issue, and I think we will
pursue that down the road. However, anecdotally there is no com-
parison, particularly in the case of a patient who can then undergo
a Nissen fundoplication. Regardless of how good the results are
with the gastric pull-up or an esophageal replacement, these pa-
tients have lifestyle modifications and reflux disease the rest of
their lives. They sleep with the head of their bed elevated, they
have to eat their evening meal early, because they are at constant
risk of regurgitation and aspiration, and that cannot be avoided. I
think it is going to end up very favorable for esophageal preserva-
tion, but it is a big issue in terms of the number of treatment
sessions necessary to get these patients to the point of having no
intestinal metaplasia.
Dr Bremner. That is quite relevant, especially with the younger
patients. There is going to be a paper discussed at this meeting re-
garding the incidence of Barrett’s esophagus in patients who have
had an esophagectomy in the proximal part of the esophagus. Most
of these patients with high-grade dysplasia are going to be cured
with an esophagectomy, but 10 to 20 years down the line, they
may still have a problem with Barrett’s esophagus.
Dr Robert Cerfolio (Birmingham, Ala). The follow-up of these
patients is the key thing to me. When you have a patient who has
a very low operative risk and you know you can probably get him
through it and cure him, deciding to do something that is ‘‘moreThe Journal of Thoracic and Cconservative’’ I would argue is less conservative. What follow-
up schedule do you use? What is the frequency, and do you use
endoscopic ultrasound routinely on your follow-up?
Dr DeMeester. No. Are you talking about an endoscopic
patient?
Dr Cerfolio. Yes.
Dr DeMeester.We do not use endoscopic ultrasound at all be-
cause it is worthless for these early lesions. The tumors have to get
deep into the submucosa or into the muscularis propria before they
can be reliably identified even with high-frequency ultrasound, so I
follow them up with routine endoscopies. They get an endoscopy
at 8 weeks after their ablative procedure and biopsies. If there is
any residual intestinal metaplasia or dysplasia, they are immedi-
ately scheduled for another ablative therapy, and that sequence
continues every 8 weeks until we get rid of all the intestinal
metaplasia.
We have learned the hard way. A few patients have had delays in
their follow-up and they have come back then with progression to
high-grade dysplasia or cancer.
Dr Cerfolio. That has been our problem as well and hence the
question. The compliance with follow-up is another issue that
needs to be considered initially as well. Let’s say they are doing
well and their intestinal metaplasia is gone. Is follow-up conducted
every 3 months, every 6 months, every year, or what?
DrDeMeester.Once all the intestinal metaplasia has been erad-
icated, then follow-up is conducted at 3 months, 6 months, and
then annually.
Dr Donald Low (Seattle, Wash). This is an important topic and
an evolving issue in surgery. I have 2 quick questions.
Endoscopic techniques are playing a larger and larger role in
virtually everything we do in the upper gastrointestinal tract.
Who is doing your interventional endoscopic procedures at the
University of Southern Califormia? Is it the surgeons or is it the
gastroenterologist?
The second question concerns assessment and decision-making.
We agree with you that treatment has to be individualized. Are all
your patients, especially those with intramucosal cancer, being
reviewed at your tumor boards?
Dr DeMeester. All these patients are treated by us as the
surgeons, and so we do all our own endoscopic procedures, our
own endoscopy follow-up, and so forth. There is no tumor
board review. We make the decision with the patient on which
way to go.ardiovascular Surgery c Volume 141, Number 1 47
